Key Companies Affected by Trump's Drug Pricing Policy : An In-Depth Look at Pharmaceutical, Biotech, and Distribution Sectors Big Pharma: Direct Exposure to Revenue CompressionMajor multinational pharmaceutical firms were among the most directly exposed to the proposed MFN pricing rule.Pfizer Inc.: As a top U.S. drugmaker with global distribution, Pfizer faced potential revenue loss on key drugs..